![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 26, 2008 1:28:25 PM
2)I think that Rebuilder Medical Technologies needs to submit to the FDA the new clinical proof of the medical claims its devices provide so they can brand and label products accordingly. (i.e. helping neuropathy by x,y,z factors)
I don't know how much each of these items would cost. If its a few thousand a quarter, then it should have already been done. If both of these things are not done, there will not be enough serious investors to counter the shorts.
Additionally, if it's not cost-prohibitive and items 1 & 2 are not done, it could be construed that there is no truth or 'half-truths' to accounting practices and the product itself. So the question still stands.......why are these things not done?
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM